{ "_meta": { "publisher": "peptide.wiki", "licence": "CC BY 4.0", "licence_url": "https://creativecommons.org/licenses/by/4.0/", "attribution": "Data: peptide.wiki (https://www.peptide.wiki/data), CC BY 4.0", "version": "2026.11", "updated": "2026-11-10" }, "data": [ { "slug": "semaglutide-vs-tirzepatide", "headline": "Semaglutide vs Tirzepatide", "description": "Semaglutide vs tirzepatide compared: receptor targets, structure, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "The core difference is receptor coverage. Semaglutide acts on the GLP-1 receptor only; tirzepatide acts on both the GIP and GLP-1 receptors. Both are fatty-acid-modified for a long half-life and both are approved medicines, so both sit at the top of our evidence scale.", "For research, semaglutide is the single-receptor reference. Tirzepatide is the natural next step when the question is what GIP-receptor activity adds." ], "url": "https://www.peptide.wiki/compare/semaglutide-vs-tirzepatide" }, { "slug": "tirzepatide-vs-retatrutide", "headline": "Tirzepatide vs Retatrutide", "description": "Tirzepatide vs retatrutide: dual vs triple agonist, GIP, GLP-1 and glucagon receptors, evidence, approval status and Nordapep pricing compared.", "verdict": [ "Retatrutide adds glucagon-receptor activity to the GIP and GLP-1 activity that tirzepatide already has. That third receptor is the whole story of the comparison.", "Tirzepatide is approved and well characterised. Retatrutide is investigational, with published phase 2 data and a phase 3 programme in progress, so its evidence picture is still changing." ], "url": "https://www.peptide.wiki/compare/tirzepatide-vs-retatrutide" }, { "slug": "semaglutide-vs-retatrutide", "headline": "Semaglutide vs Retatrutide", "description": "Semaglutide vs retatrutide: single GLP-1 agonist vs GIP/GLP-1/glucagon triple agonist, compared on evidence, structure and Nordapep price.", "verdict": [ "This pairing spans the whole incretin story: one receptor versus three. Semaglutide is the established single-receptor medicine; retatrutide is the investigational triple agonist.", "Many labs study all three incretin peptides together, which is why Nordapep's GLP-1 Research Trio exists." ], "url": "https://www.peptide.wiki/compare/semaglutide-vs-retatrutide" }, { "slug": "bpc-157-vs-tb-500", "headline": "BPC-157 vs TB-500", "description": "BPC-157 vs TB-500 compared: origin, structure, what the research studies, evidence quality and Nordapep price per mg.", "verdict": [ "These are often mentioned together but are unrelated molecules. BPC-157 is a 15-residue peptide derived from a gastric-juice protein. TB-500 is a fragment of thymosin beta-4, an actin-regulating protein.", "Both have mostly preclinical evidence. BPC-157 has the larger published literature; TB-500 has an extra identity problem because suppliers use the name for different constructs, so mass-spectrometry data matter." ], "url": "https://www.peptide.wiki/compare/bpc-157-vs-tb-500" }, { "slug": "cjc-1295-vs-ipamorelin", "headline": "CJC-1295 vs Ipamorelin", "description": "CJC-1295 vs ipamorelin: GHRH analogue vs ghrelin-receptor agonist, structure, selectivity, evidence and the Nordapep blend compared.", "verdict": [ "They act on two different pituitary receptors. CJC-1295 is a GHRH analogue acting at the GHRH receptor; ipamorelin is a ghrelin-receptor agonist. That is why they are so often studied together rather than instead of each other.", "Neither is approved and both have only small human datasets. Nordapep supplies them as a single pre-blended vial." ], "url": "https://www.peptide.wiki/compare/cjc-1295-vs-ipamorelin" }, { "slug": "pt-141-vs-melanotan-2", "headline": "PT-141 vs Melanotan II", "description": "PT-141 (bremelanotide) vs Melanotan II: receptor selectivity, approval status, evidence and Nordapep pricing compared.", "verdict": [ "PT-141 was derived from melanotan II. The key difference is selectivity: melanotan II activates several melanocortin receptors broadly, while PT-141 acts more selectively on central receptors, mainly MC4R.", "PT-141 is FDA-approved for one indication; melanotan II has never been approved and has drawn regulator warnings about unlicensed products." ], "url": "https://www.peptide.wiki/compare/pt-141-vs-melanotan-2" }, { "slug": "semax-vs-selank", "headline": "Semax vs Selank", "description": "Semax vs Selank compared: parent peptides, research focus, evidence and regulatory status, plus Nordapep prices.", "verdict": [ "Both are Russian-developed heptapeptides that share a stabilising Pro-Gly-Pro tail, but their parent sequences differ. Semax comes from ACTH(4-10) and is studied for neurotrophic signalling; Selank comes from tuftsin and is studied for stress-response and GABAergic pathways.", "Both are registered medicines in Russia only, and both have limited independent replication elsewhere." ], "url": "https://www.peptide.wiki/compare/semax-vs-selank" }, { "slug": "liraglutide-vs-semaglutide", "headline": "Liraglutide vs Semaglutide", "description": "Liraglutide vs semaglutide compared: acylation, half-life, evidence level and regulatory status of two approved GLP-1 receptor agonists.", "verdict": [ "Both are acylated GLP-1 analogues that act on the GLP-1 receptor only, and both are approved medicines. The difference is in the engineering: semaglutide has a different N-terminal substitution and a longer fatty-diacid linker, which gives it a half-life of about a week against roughly 13 hours for liraglutide.", "For research, liraglutide is the older reference with the longest published record. Semaglutide is the more current benchmark and the usual starting point when a study needs a long-acting GLP-1 comparator." ], "url": "https://www.peptide.wiki/compare/liraglutide-vs-semaglutide" }, { "slug": "semaglutide-vs-cagrilintide", "headline": "Semaglutide vs Cagrilintide", "description": "Semaglutide vs cagrilintide: GLP-1 versus amylin pathways, structure, evidence and regulatory status, and how CagriSema combines them.", "verdict": [ "These two act on different hormone systems. Semaglutide mimics GLP-1 and activates the GLP-1 receptor. Cagrilintide mimics amylin and activates amylin and calcitonin receptors. Both are acylated for a half-life of about a week.", "Semaglutide is an approved medicine and cagrilintide is investigational on its own. Their combination, CagriSema, was submitted to the FDA in December 2025 and was still under review at the time of writing." ], "url": "https://www.peptide.wiki/compare/semaglutide-vs-cagrilintide" }, { "slug": "tesamorelin-vs-cjc-1295", "headline": "Tesamorelin vs CJC-1295", "description": "Tesamorelin vs CJC-1295: full-length versus truncated GHRH analogues, structure, evidence and regulatory status compared.", "verdict": [ "Both are GHRH analogues acting on the same pituitary receptor. Tesamorelin keeps the full 44-residue GHRH sequence and adds an N-terminal hexenoyl group. CJC-1295 is built on the first 29 residues and comes in versions with and without a drug affinity complex (DAC) that differ greatly in half-life.", "Tesamorelin is an FDA-approved medicine for one indication with a phase 3 evidence base. CJC-1295 has never been approved and has only small early human datasets. Tesamorelin is the better-documented benchmark, while CJC-1295 is more often studied alongside ghrelin-receptor agonists." ], "url": "https://www.peptide.wiki/compare/tesamorelin-vs-cjc-1295" }, { "slug": "ipamorelin-vs-ghrp-6", "headline": "Ipamorelin vs GHRP-6", "description": "Ipamorelin vs GHRP-6: two ghrelin-receptor agonists compared on structure, selectivity, evidence and regulatory status.", "verdict": [ "Both activate the ghrelin (GHS) receptor. GHRP-6 is a six-residue, first-generation compound. Ipamorelin is a five-residue compound developed later with a more selective profile.", "In the published studies GHRP-6 also affects cortisol, prolactin and feeding behaviour, while ipamorelin shows little effect on cortisol or prolactin. Neither is approved and both rest on small, older human datasets." ], "url": "https://www.peptide.wiki/compare/ipamorelin-vs-ghrp-6" }, { "slug": "afamelanotide-vs-melanotan-2", "headline": "Afamelanotide vs Melanotan II", "description": "Afamelanotide (melanotan I) vs melanotan II: structure, receptor profile, evidence and regulatory status compared.", "verdict": [ "Both came out of the same University of Arizona research programme, but they are different molecules. Afamelanotide, or melanotan I, is a linear 13-residue α-MSH analogue acting mainly at MC1R. Melanotan II is a shorter cyclic peptide that activates several melanocortin receptors.", "Afamelanotide went through formal clinical development and is an approved medicine for one rare condition in the EU and US. Melanotan II has never been approved, and regulators have warned about unlicensed products sold under the melanotan name." ], "url": "https://www.peptide.wiki/compare/afamelanotide-vs-melanotan-2" }, { "slug": "setmelanotide-vs-pt-141", "headline": "Setmelanotide vs PT-141", "description": "Setmelanotide vs PT-141: two MC4R-active peptides compared on structure, receptor profile, approvals and evidence.", "verdict": [ "Both peptides activate the melanocortin-4 receptor, but they come from different design lineages. PT-141 (bremelanotide) derives from melanotan II and also touches other melanocortin receptors. Setmelanotide is a separate cyclic octapeptide designed around MC4R.", "Both are approved medicines for narrow indications, which is unusual in this class. PT-141 is FDA-approved only, while setmelanotide has authorisations in the UK, EU and US for specific genetic conditions. Neither approval says anything about research material." ], "url": "https://www.peptide.wiki/compare/setmelanotide-vs-pt-141" }, { "slug": "mots-c-vs-ss-31", "headline": "MOTS-c vs SS-31", "description": "MOTS-c vs SS-31: a mitochondria-encoded peptide versus a mitochondria-targeted peptide, compared on origin, structure, evidence and approval status.", "verdict": [ "Both appear in mitochondrial research, but they work in opposite ways. MOTS-c is a natural 16-residue peptide encoded by mitochondrial DNA that acts as a signal from the mitochondrion to the rest of the cell. SS-31 is a synthetic four-residue peptide designed to enter mitochondria and bind cardiolipin.", "The evidence is also very different. SS-31 (elamipretide) has an FDA accelerated approval for one rare condition and a mixed set of phase 3 results. MOTS-c has no human interventional trials and relies mainly on cell and mouse work." ], "url": "https://www.peptide.wiki/compare/mots-c-vs-ss-31" }, { "slug": "thymosin-alpha-1-vs-tb-500", "headline": "Thymosin Alpha-1 vs TB-500", "description": "Thymosin alpha-1 vs TB-500 (a thymosin beta-4 fragment): origin, structure, function, evidence and approval status compared.", "verdict": [ "These are often confused because of the family name, but they are unrelated. Thymosin alpha-1 is a 28-residue, N-acetylated peptide from the precursor prothymosin alpha, studied for immune signalling. TB-500 is a fragment of thymosin beta-4, an actin-binding protein, studied in cell-migration and wound models.", "Thymosin alpha-1 has late-stage human data and is approved as thymalfasin in a number of countries, though not by the FDA. TB-500 has only preclinical data, and different suppliers use the name for different constructs." ], "url": "https://www.peptide.wiki/compare/thymosin-alpha-1-vs-tb-500" }, { "slug": "exenatide-vs-liraglutide", "headline": "Exenatide vs Liraglutide", "description": "Exenatide vs liraglutide compared: exendin-4 origin vs acylated human GLP-1 analogue, structure, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "Both activate the GLP-1 receptor, but they get there differently. Exenatide is a 39-residue copy of exendin-4 from Gila monster saliva with no lipid chain. Liraglutide is a modified human GLP-1 analogue carrying a fatty acid that binds albumin and extends its half-life.", "For research, exenatide is the reference for the non-mammalian, DPP-4-resistant backbone. Liraglutide is the reference for fatty-acid acylation as a half-life strategy." ], "url": "https://www.peptide.wiki/compare/exenatide-vs-liraglutide" }, { "slug": "sermorelin-vs-cjc-1295", "headline": "Sermorelin vs CJC-1295", "description": "Sermorelin vs CJC-1295 compared: GHRH analogues, structure, half-life design, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "Both act on the GHRH receptor. Sermorelin is the native 1-29 fragment of GHRH and has a half-life of minutes. CJC-1295 is a modified analogue engineered for greater stability and a longer duration.", "For research, sermorelin is the natural baseline for GHRH-receptor work and has a history as an approved product. CJC-1295 is the choice when a longer-acting GHRH analogue is the subject." ], "url": "https://www.peptide.wiki/compare/sermorelin-vs-cjc-1295" }, { "slug": "hexarelin-vs-ghrp-6", "headline": "Hexarelin vs GHRP-6", "description": "Hexarelin vs GHRP-6 compared: related ghrelin-receptor agonists, potency, desensitisation, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "Both are first-generation synthetic ghrelin-receptor agonists, and both are six residues long. Hexarelin is generally reported as the more potent of the two, while the published work also highlights how rapidly the receptor response to it fades.", "For research, GHRP-6 is the classic reference compound. Hexarelin is useful when receptor desensitisation or cardiac-binding questions are the focus." ], "url": "https://www.peptide.wiki/compare/hexarelin-vs-ghrp-6" }, { "slug": "pramlintide-vs-cagrilintide", "headline": "Pramlintide vs Cagrilintide", "description": "Pramlintide vs cagrilintide compared: short-acting vs long-acting amylin analogues, structure, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "Both are amylin analogues, but they come from different design strategies. Pramlintide is a 37-residue human amylin with three proline substitutions, a short-acting soluble version. Cagrilintide is an acylated analogue built for a much longer duration.", "For research, pramlintide is the established approved reference for amylin receptor pharmacology. Cagrilintide is the reference for long-acting amylin analogue design." ], "url": "https://www.peptide.wiki/compare/pramlintide-vs-cagrilintide" }, { "slug": "survodutide-vs-retatrutide", "headline": "Survodutide vs Retatrutide", "description": "Survodutide vs retatrutide compared: two-receptor vs three-receptor design, structure, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "The core difference is receptor coverage. Survodutide activates the GLP-1 and glucagon receptors; retatrutide activates those two plus the GIP receptor. Both are fatty-acid-modified for a long half-life and both are investigational, so neither is an approved medicine outside the regional exceptions noted on their pages.", "For research, survodutide is the cleaner tool when the question is what glucagon-receptor activity adds to GLP-1 activity. Retatrutide is the natural choice when the question is how a third (GIP) receptor changes the picture." ], "url": "https://www.peptide.wiki/compare/survodutide-vs-retatrutide" }, { "slug": "mazdutide-vs-survodutide", "headline": "Mazdutide vs Survodutide", "description": "Mazdutide vs survodutide compared: two GLP-1 and glucagon dual agonists, structure, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "Both compounds activate the GLP-1 and glucagon receptors, but they are different molecules. Mazdutide is an oxyntomodulin analogue developed in China and approved there for obesity; survodutide is built on a glucagon-like backbone and remains investigational.", "For research, the comparison is useful because it holds the receptor pair constant while the backbone and fatty-acid design differ. Most human data for mazdutide come from Chinese study populations, while survodutide's phase 3 programme is international." ], "url": "https://www.peptide.wiki/compare/mazdutide-vs-survodutide" }, { "slug": "ghrp-2-vs-ghrp-6", "headline": "GHRP-2 vs GHRP-6", "description": "GHRP-2 vs GHRP-6 compared: two ghrelin-receptor peptides, structure, evidence level, regulatory status and Nordapep price per mg.", "verdict": [ "Both are six-residue peptides that activate the ghrelin (GHS-R1a) receptor, and both sit in the original growth hormone releasing peptide family. They differ in sequence and in how they affect other pituitary hormones and appetite signalling in published studies.", "For research, GHRP-6 is the original reference compound and GHRP-2 is the more potent follow-on. Only GHRP-2 has a regulatory approval, as a diagnostic agent in Japan." ], "url": "https://www.peptide.wiki/compare/ghrp-2-vs-ghrp-6" } ] }